MassDevice.com +5 | The top 5 medtech stories for July 17, 2017

Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. OrthoSensor raises $6.3m OrthoSensor raised $6.3 million in a new round of mixed financing, according to an SEC filing posted this week. Money in the round came from 15 unnamed sources, according to the SEC filing, with the 1st sale recorded on April 10 this year. OrthoSensor is not looking to raise anymore funds in the round. Read more 4. Medtronic touts 5-year data on InterStim neuromod device for OAB Medtronic today touted 5-year results from the InSite study of its InterStim neuromodulation treatment for overactive bladder syndrome. InterStim is designed to stimulate the sacral nerve to treat OAB, meaning urinary urge incontinence and/or urgency-frequency. The InSite study enrolled 340 patients, of which 272 were implanted with an InterStim device, comparing treatment with the device with standard drug therapy. The primary safety endpoint was to “demonstrate that the upper bound of the 95% CI for the cumulative five-year rate of adverse events related to the tined lead that require surgery is less than 33%” at 5 years, according to ClinicalTrials.gov. The primary e...
Source: Mass Device - Category: Medical Devices Authors: Tags: News Well Plus 5 Source Type: news